Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial
ASCO 2026
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (Abstract LBA1006).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Giredestrant is being designed as an oral SERD and complete ER antagonist. We've already seen two positive phase III trials with giredestrant, evERA in combination with everolimus in the metastatic setting and lidERA as a single agent better than standard endocrine therapy in the adjuvant setting. So persevERA is the third phase III study to report with giredestrant, and this looked at the first-line setting in patients with metastatic ER-positive, HER2-negative advanced breast cancer. Standard of care here is, of course, an aromatase inhibitor and a CDK4/6 inhibitor. And persevERA was designed to assess whether switching from an AI to giredestrant could improve PFS. So the study randomized just under 1,000 patients between letrozole and palbociclib and giredestrant and palbociclib in a double-blind fashion. And the primary endpoint was investigator-assessed PFS. Overall, the study was negative. There was no statistically significant improvement in PFS. The hazard ratio was 0.89, but there clearly appeared to be a numerical improvement of PFS with giredestrant. The curves, interestingly, appeared to be overlapping for the first 12 months, perhaps suggesting that early recurrences are not driven by ER; they're driven by other mechanisms of resistance, and then the curves appear to separate. Potentially, giredestrant here is active because these later recurrences are driven, it's preventing the emergence of ESR1 mutations. And so, overall, the study does confirm the high activity of giredestrant, but not better than an aromatase inhibitor in this study combined with palbociclib.
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
The ASCO Post Staff
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanubrutinib for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as the doublet’s effect on measurable residual disease (Abstract 7043). He also discusses the phase III BGB-11417-304/CELESTIAL-TNCLL-2 trial; this ongoing study is evaluating sonrotoclax plus zanubrutinib vs venetoclax and acalabrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) (Abstract TPS7099).
The ASCO Post Staff
Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).
The ASCO Post Staff
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).
Lucy Gilbert, MD, of McGill University Health Centre, discusses subgroup analyses from the ROSELLA study. Relacorilant plus nab-paclitaxel demonstrated a statistically and clinically significant overall survival benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane; subgroup analyses for overall survival showed a consistent benefit favoring the addition of relacorilant to nab-paclitaxel irrespective of prior taxane use (Abstract 5503).